临床试验/NCT04724031

NCT04724031进行中（未招募）不适用

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Hellenic Cooperative Oncology Group1 个研究点分布在 1 个国家目标入组 150 人开始时间: 2019年11月1日最近更新: 2023年3月14日

适应症

干预措施

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 150
试验地点: 1
主要终点: Evaluation of Progression Free Survival

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.

详细描述

A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.

研究设计

研究类型: Observational
观察模型: Other
时间视角: Other

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•women >18 years old with advanced high grade ovarian cancer

排除标准

未提供

研究组 & 干预措施

One cohort

women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment

干预措施: PARP inhibitor (Drug)

结局指标

主要结局

Evaluation of Progression Free Survival

时间窗: 12/2022

次要结局

Assessment of the safety profile of olaparib in women with advanced high grade ovarian cancer(12/2021)
Assessment of the safety profile of niraparib in women with advanced high grade ovarian cancer(12/2021)

研究者

发起方

Hellenic Cooperative Oncology Group

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

招募中

不适用

Real-world Data in Patients With Breast Cancer Treated With AbemaciclibBreast Cancer

NCT04985058Hellenic Cooperative Oncology Group108

Unknown

不适用

Advanced Refractory Solid Tumors With TP53 Mutations Register StudySolid Tumor, Adult

NCT03927599Tianjin Medical University Second Hospital100

已完成

不适用

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03896984Bayer346

招募中

2 期

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)Sarcoma,Soft TissueSarcoma of BoneSarcoma

NCT06074692Ruijin Hospital86

招募中

不适用

Drug-drug Interactions With Anti-tuberculous DrugsDrug-drug Interaction

NCT06381375Cairo University400